ClinConnect ClinConnect Logo
Search / Trial NCT01177826

Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children

Launched by GLAXOSMITHKLINE · Aug 6, 2010

Trial Information

Current as of May 24, 2025

Completed

Keywords

Hospitalized Rotavirus Children Effectiveness Gastroenteritis

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • For confirmed cases:
  • A male or female child born after 01 October 2006 and at least 14 weeks of age at the time of hospital admission.
  • Child admitted at the study hospital for SGE during the study period.
  • Onset of SGE ≤ 14 days prior to admission.
  • Written informed consent obtained and signed from the parent or guardian of the child.
  • Stool samples collected during the first 48 hours of hospitalisation and then tested positive for RV by PCR.
  • For controls:
  • A male or female child born after 01 October 2006 and at least 14 weeks of age at the time of the hospital admission or visit to the hospital outpatient clinic.
  • Hospitalised or visiting the hospital outpatient clinic for non-GE causes at the same hospital during the same time-period, as the probable case.
  • Born within ±2 weeks from the date of birth of the case. If the list of children born within ±2 weeks is exhausted, then the range will be extended to ±4 weeks. In case a suitable control is not found even then, the range will be extended to ±6 weeks.
  • Written informed consent obtained and signed from the parent or guardian of the child.
  • Exclusion Criteria:
  • For cases:
  • Child has previously participated as a case or a control in this study, either in the same hospital or in another study hospital.
  • Onset of SGE \>48 hours after admission to the hospital (nosocomial infections).
  • Child with a condition where rotavirus vaccination would be contraindicated.
  • For controls:
  • Child has participated in the past as a case or control in this study, either in the same hospital or in another study hospital.
  • Child who has symptoms of GE/ SGE during current hospital stay/ visit to the hospital outpatient clinic or on the day of interview of his/her parent or guardian.
  • Child with a condition where rotavirus vaccination would be contraindicated.

About Glaxosmithkline

GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.

Locations

Edegem, , Belgium

Antwerpen, , Belgium

Gent, , Belgium

Hasselt, , Belgium

Kortrijk, , Belgium

Mons, , Belgium

Wilrijk, , Belgium

Genk, , Belgium

Ottignies, , Belgium

Bruxelles, , Belgium

Gosselies, , Belgium

Merksem, , Belgium

Namur, , Belgium

Oostende, , Belgium

Deurne, , Belgium

Hornu, , Belgium

Deinze, , Belgium

Roeselaere, , Belgium

Chimay, , Belgium

Eeklo, , Belgium

Heusden, , Belgium

Ieper, , Belgium

Nivelles, , Belgium

Sint Niklaas, , Belgium

Sint Truiden, , Belgium

Tongeren, , Belgium

Patients applied

0 patients applied

Trial Officials

GSK Clinical Trials

Study Director

GlaxoSmithKline

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials